Journal of the American Society of Nephrology, Vol 9, 2223-2234, Copyright © 1998 by American Society of Nephrology

REGULAR ARTICLES

Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension

J Plum, B Bunten, R Nemeth and B Grabensee
Department of Nephrology and Rheumatology, Medizinische Einrichtungen der Heinrich Heine Universitat, Dusseldorf, Germany.

Angiotensin II receptor antagonists have become clinically available for the treatment of arterial hypertension. Presently, there is little information about their effects on BP, proteinuria, and renal function in patients with moderate or advanced renal failure. This study examines the effects of the angiotensin II antagonist Valsartan (80 mg/d) on proteinuria and glomerular permselectivity in patients with chronic renal failure during a 6-mo treatment, using a double-blind, randomized, placebo-controlled study (treatment group [V-group]: n = 5, age 57 +/- 7 yr, serum creatinine 365 +/- 122 micromol/L; placebo group [P-group]: n = 4, age 62 +/- 11 yr, serum creatinine 346 +/- 61 micromol/L). Study parameters included BP, 24-h proteinuria, GFR, and effective renal plasma flow (ERPF) as determined by inulin and para- aminohippurate clearance. Changes in glomerular permselectivity were assessed by measuring the fractional clearances of neutral dextrans by HPLC gel-permeation chromatography. Valsartan lowered the mean arterial pressure on average by 13 +/- 7 mmHg during the 6-mo treatment (P < 0.05). GFR and ERPF remained almost unchanged. However, after 6 mo of Valsartan treatment, proteinuria was reduced by 396 +/- 323 mg/24 h (26 +/- 18%) and albuminuria by 531 +/- 499 mg/24 h (41 +/- 21%) with regard to baseline values (P < 0.05). In the P-group, both proteinuria and albuminuria increased slightly with time (by 30 +/- 43% and 30 +/- 54%, respectively, NS). The fractional clearances of high molecular weight dextrans >66 A were significantly reduced after 6 mo of Valsartan treatment (P < 0.05), indicating a reduction of the glomerular shunt volume by 54 +/- 20% (P < 0.05) according to the model of Deen et al. (Am J Physiol 249: 347-389, 1985). The mean pore size radius of the glomerular membrane remained unchanged. This effect was independent of glomerular hemodynamic changes. Valsartan persistently lowered proteinuria in patients with chronic renal failure. Although GFR and ERPF remained nearly stable, this effect could be attributed to an improvement in glomerular permselectivity.

This article has been cited by other articles:

				N. Hashimoto, Y. Maeshima, M. Satoh, M. Odawara, H. Sugiyama, N. Kashihara, H. Matsubara, Y. Yamasaki, and H. Makino Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model Am J Physiol Renal Physiol, March 1, 2004; 286(3): F516 - F525. [Abstract] [Full Text]

				H. Suzuki, T. Yamamoto, N. Ikegaya, and A. Hishida Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression Am J Physiol Renal Physiol, February 1, 2004; 286(2): F267 - F277. [Abstract] [Full Text] [PDF]

				M. Praga, C. F. Andrade, J. Luno, M. Arias, R. Poveda, J. Mora, M. V. Prat, F. Rivera, J. M. Galceran, J. M. Ara, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1806 - 1813. [Abstract] [Full Text] [PDF]

				J. Segura, M. Praga, C. Campo, J. L Rodicio, and L. M Ruilope Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 43 - 47. [Abstract] [PDF]

				M. A J Devonald and F. E Karet Targeting the renin-angiotensin system in patients with renal disease J R Soc Med, January 8, 2002; 95(8): 391 - 397. [Full Text] [PDF]

				G. L. Bakris A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients Arch Intern Med, December 10, 2001; 161(22): 2661 - 2667. [Abstract] [Full Text] [PDF]

				R. Toto Angiotensin II Subtype 1 Receptor Blockers and Renal Function Arch Intern Med, June 25, 2001; 161(12): 1492 - 1499. [Abstract] [Full Text] [PDF]

				A. J. P. Lewington, M. Arici, K. P. G. Harris, N. J. Brunskill, and J. Walls Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits? Nephrol. Dial. Transplant., May 1, 2001; 16(5): 885 - 888. [Full Text] [PDF]

				M. Burnier Angiotensin II Type 1 Receptor Blockers Circulation, February 13, 2001; 103(6): 904 - 912. [Full Text] [PDF]

				A. SCHWARZ New Aspects of the Treatment of Nephrotic Syndrome J. Am. Soc. Nephrol., February 1, 2001; 12(90001): S44 - S47. [Abstract] [Full Text] [PDF]

				E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]

				L. M Ruilope New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2_suppl): S29 - S31. [Abstract] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673